Skip to content

A phase II study of radiotherapy for mCRPC oligometastatic prostate cancer

A phase II study of radiotherapy for mCRPC oligometastatic prostate cancer

Status
Recruiting
Phases
Phase 2
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OIC-17013473
Enrollment
Unknown
Registered
2017-11-21
Start date
2017-11-21
Completion date
Unknown
Last updated
2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Case series:Radiotherapy + ADT

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Histologic confirmation of malignancy (primary or metastatic tumor); 2. Castration-resistant prostate cancer (CRPC); 3. Patient must have 1-3 asypmtomatic metastatic tumor(s) of the bone or soft tissue; 4. Patient may have had prior systemic therapy and/or ADT associated with treatment of their primary prostate cancer; 5. Patient must be = 18 years of age, have the ability to understand, and the willingness to sign, a written informed consent document; 6. Patient must have an Eastern Cooperative Oncology Group performance status = 2.

Exclusion criteria

Exclusion criteria: 1. can not tolerate RT because of seriously pain or other diseases; 2. life expectancyx< 6 months

Design outcomes

Primary

MeasureTime frame
OS;OS;

Secondary

MeasureTime frame
acute toxicity of RT;late toxicity of RT;time to first imaging progress;PCSS;

Countries

China

Contacts

Public ContactXianshu Gao

Peking University First Hospital

13911208977@139.com+86 10 83575239

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026